Armistice Capital LLC Cuts Stock Holdings in Aurinia Pharmaceuticals Inc $AUPH

Key Points

• Armistice Capital LLC has reduced its holdings in Aurinia Pharmaceuticals by 21.9%, selling 1,400,000 shares to hold a total of 5,000,000 shares valued at approximately $40.2 million.
• Director Kevin Tang significantly increased his stake, purchasing 1,000,000 shares for $10.12 each, raising his total ownership to 11,029,500 shares, valued at over $111 million.
• Aurinia Pharmaceuticals reported earnings of $0.16 per share, slightly missing estimates, but its revenue of $70.01 million exceeded expectations of $64.27 million, indicating steady growth in the biotech sector.

Armistice Capital LLC decreased its position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 21.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,000,000 shares of the biotechnology company's stock after selling 1,400,000 shares during the quarter. Armistice Capital LLC owned 3.66% of Aurinia Pharmaceuticals worth $40,200,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of AUPH. Raymond James Financial Inc. bought a new stake in Aurinia Pharmaceuticals during the fourth quarter worth about $215,000. MetLife Investment Management LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 3.5% in the fourth quarter. MetLife Investment Management LLC now owns 85,680 shares of the biotechnology company's stock worth $769,000 after acquiring an additional 2,918 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 2,635 shares during the last quarter. Hsbc Holdings PLC lifted its holdings in shares of Aurinia Pharmaceuticals by 48.2% in the fourth quarter. Hsbc Holdings PLC now owns 15,616 shares of the biotechnology company's stock worth $141,000 after acquiring an additional 5,080 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Aurinia Pharmaceuticals by 19.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 52,098 shares of the biotechnology company's stock worth $468,000 after acquiring an additional 8,350 shares during the last quarter. Institutional investors own 36.83% of the company's stock.

Aurinia Pharmaceuticals Stock Up 0.0%

NASDAQ AUPH traded up $0.01 during mid-day trading on Friday, hitting $12.54. The company's stock had a trading volume of 867,679 shares, compared to its average volume of 1,627,993. The company's 50 day simple moving average is $10.21 and its 200 day simple moving average is $8.79. Aurinia Pharmaceuticals Inc has a twelve month low of $6.42 and a twelve month high of $12.82. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of 29.04 and a beta of 1.26.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.01). Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The business had revenue of $70.01 million during the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current year.

Analyst Ratings Changes

AUPH has been the subject of a number of research reports. HC Wainwright reiterated a "buy" rating and issued a $17.00 price target on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 30th. Royal Bank Of Canada raised their price objective on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a report on Friday, August 1st. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $12.00.

Insiders Place Their Bets

In other Aurinia Pharmaceuticals news, Director Kevin Tang purchased 1,000,000 shares of the company's stock in a transaction that occurred on Friday, August 1st. The shares were acquired at an average price of $10.12 per share, with a total value of $10,120,000.00. Following the transaction, the director owned 11,029,500 shares in the company, valued at $111,618,540. The trade was a 9.97% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders have bought 1,300,000 shares of company stock valued at $13,590,000. 12.20% of the stock is currently owned by company insiders.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.